SummaryGlobal Markets Direct’s, Neuralgia - Pipeline Review, H2 2012, provides anoverview of the indication’s therapeutic pipeline. This report providesinformation on the therapeutic development for Neuralgia, complete with latestupdates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for Neuralgia.Neuralgia - Pipeline Review, Half Year is built using data and informationsourced from Global Markets Direct’s proprietary databases,Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Neuralgia.- A review of the Neuralgia products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Neuralgia.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.
Table of Contents :List of Tables 8List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Neuralgia Overview 11Therapeutics Development 12An Overview of Pipeline Products for Neuralgia 12Neuralgia Therapeutics under Development by Companies 14Neuralgia Therapeutics under Investigation by Universities/Institutes 18Late Stage Products 20Comparative Analysis 20Mid Clinical Stage Products 21Comparative Analysis 21Early Clinical Stage Products 22Comparative Analysis 22Discovery and Pre-Clinical Stage Products 23Comparative Analysis 23Neuralgia Therapeutics – Products under Development by Companies 24Neuralgia Therapeutics – Products under Investigation byUniversities/Institutes 25…………………..
Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=PipelineReview, H2 2012&PubId=&pagenum=1
For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: email@example.com ,firstname.lastname@example.orgURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore